Arora, Mansi
Bogenberger, James M.
Abdelrahman, Amro
Leiting, Jennifer L.
Chen, Xianfeng
Egan, Jan B.
Kasimsetty, Aradhana
Lenkiewicz, Elzbieta
Malasi, Smriti
Uson, Pedro Luiz Serrano
Nagalo, Bolni Marius
Zhou, Yumei
Salomao, Marcela A.
Kosiorek, Heidi E.
Braggio, Esteban
Barrett, Michael T.
Truty, Mark J.
Borad, Mitesh J. http://orcid.org/0000-0003-2700-2658
Funding for this research was provided by:
Center for Individualized Medicine, Mayo Clinic
Article History
Received: 16 January 2020
Accepted: 7 May 2020
First Online: 21 May 2020
Compliance with ethical standards
:
: JMB owns purchased stock of Clovis Oncology. MJB has received grant to institution from Senhwa Pharmaceuticals, Adaptimmune, Agios Pharmaceuticals, Halozyme Pharmaceuticals, Celgene Pharmaceuticals, EMD Merck Serono, Toray, Dicerna, Taiho Pharmaceuticals, Sun Biopharma, Isis Pharmaceuticals, Redhill Pharmaceuticals, Boston Biomed, Basilea, Incyte Pharmaceuticals, Mirna Pharmaceuticals, Medimmune, Bioline, Sillajen, ARIAD Pharmaceuticals, PUMA Pharmaceuticals, Novartis Pharmaceuticals, QED Pharmaceuticals, Pieris Pharmaceuticals, consultancy from ADC Therapeutics, Exelixis Pharmaceuticals, Inspyr Therapeutics, G1 Therapeutics, Immunovative Therapies, OncBioMune Pharmaceuticals, Western Oncolytics, Lynx Group, and travel support from Astra Zeneca. The remaining authors have no conflicts of interest to declare.